FCRL5 and granulomatosis with polyangiitis: Finally, while B cell count in peripheral blood has been routinely used to guide therapeutic decisions in patients on rituximab treatment, a recent trial explored the baseline expression of Fc receptor-like 5 (FCRL5), a marker of both naïve and memory B cells, as a biomarker of treatment response in patients with GPA and MPA [81].